• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺动脉高压的保罗·伍德法。

Pulmonary Hypertension by the Method of Paul Wood.

机构信息

Pulmonary Circulation Center, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN.

出版信息

Chest. 2020 Sep;158(3):1164-1171. doi: 10.1016/j.chest.2020.02.035. Epub 2020 Mar 6.

DOI:10.1016/j.chest.2020.02.035
PMID:32147248
Abstract

A physiological approach to the analysis of hemodynamic data in pulmonary hypertension (PH) has the advantage of reducing the large number (well over 100) of potential causal illnesses into four simple mechanisms. A fifth condition is composed of mixtures of the four basic mechanisms. This approach was beautifully described by Paul Wood, the great cardiologist whose name is given to the units of pulmonary vascular resistance (PVR), Wood units. This approach uses well understood physiological contributions to pulmonary vascular pressure. It is powerful, the major uncertainty being in determination of the magnitude of each mechanism in patients that have mixed PH of several causes. It also makes sense of the occasionally awkward clustering of conditions in the clinical classification of the World Symposium, which omits pulmonary vasoconstriction, hyperkinetic states, and the highly prevalent condition of "mixed" PH. This method of analysis is described and demonstrated, much as Wood did in his writings. The method is useful in the office, the ICU, and in consultation. A basic message from this approach is that correct assessment requires measurement of each of the three major inputs, pulmonary arterial pressure (Ppa), pulmonary artery wedge pressure (Pwedge) and cardiac output (CO). Some cases also need left ventricular end diastolic pressure (LVEDP). Other data contributing to analysis will be discussed in each condition. A key to avoiding mistakes is to always remember that PH is simply an elevation in pressure and is not inherently diagnostic of cause.

摘要

一种分析肺动脉高压(PH)血流动力学数据的生理学方法具有将大量(超过 100 种)潜在病因疾病简化为四种简单机制的优势。第五种情况由四种基本机制的混合组成。这种方法由伟大的心脏病学家 Paul Wood 出色地描述过,他的名字被赋予了肺血管阻力(PVR)的单位,即 Wood 单位。这种方法使用了对肺血管压力有深入了解的生理学贡献。它非常强大,主要的不确定性在于确定具有多种病因的混合 PH 患者中每种机制的程度。它还解释了世界研讨会临床分类中偶尔出现的条件聚类的情况,该分类省略了肺血管收缩、高动力状态和高度普遍的“混合”PH 条件。这种分析方法与 Wood 在他的著作中所描述的方法类似。该方法在办公室、重症监护室和咨询中都很有用。这种方法的一个基本信息是,正确的评估需要测量三个主要输入中的每一个,即肺动脉压(Ppa)、肺动脉楔压(Pwedge)和心输出量(CO)。有些病例还需要测量左心室舒张末期压(LVEDP)。每种情况下还将讨论有助于分析的其他数据。避免错误的关键是始终记住,PH 只是压力升高,本身并不能诊断病因。

相似文献

1
Pulmonary Hypertension by the Method of Paul Wood.肺动脉高压的保罗·伍德法。
Chest. 2020 Sep;158(3):1164-1171. doi: 10.1016/j.chest.2020.02.035. Epub 2020 Mar 6.
2
Can echocardiographic evaluation of cardiopulmonary hemodynamics decrease right heart catheterizations in end-stage heart failure patients awaiting transplantation?超声心动图评估心肺血液动力学能否减少等待移植的终末期心力衰竭患者的右心导管检查?
Am J Cardiol. 2010 Dec 1;106(11):1657-62. doi: 10.1016/j.amjcard.2010.07.022. Epub 2010 Oct 14.
3
Usefulness of pulmonary capillary wedge pressure as a correlate of left ventricular filling pressures in pulmonary arterial hypertension.肺毛细血管楔压作为肺动脉高压中左心室充盈压相关指标的效用。
J Heart Lung Transplant. 2014 Feb;33(2):157-62. doi: 10.1016/j.healun.2013.10.008. Epub 2013 Oct 11.
4
Characterization of patients with borderline pulmonary arterial pressure.特发性肺动脉高压患者的特征。
Chest. 2014 Dec;146(6):1486-1493. doi: 10.1378/chest.14-0194.
5
Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia.遗传性出血性毛细血管扩张症中的肺动脉高压。
Chest. 2016 Feb;149(2):362-371. doi: 10.1378/chest.15-0535. Epub 2016 Jan 12.
6
Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension.心室舒张压比值作为肺动脉高压治疗反应的标志物
Chest. 2017 Nov;152(5):980-989. doi: 10.1016/j.chest.2017.05.008. Epub 2017 May 17.
7
Pulmonary artery acceleration time in identifying pulmonary hypertension patients with raised pulmonary vascular resistance.肺动脉加速时间在识别肺动脉高压伴肺血管阻力升高患者中的作用。
Eur Heart J Cardiovasc Imaging. 2013 Sep;14(9):890-7. doi: 10.1093/ehjci/jes309. Epub 2013 Jan 7.
8
Prognostic value and diagnostic properties of the diastolic pulmonary pressure gradient in patients with pulmonary hypertension and left heart disease.肺动脉高压合并左心疾病患者舒张期肺动静脉压力梯度的预后价值及诊断特性。
Int J Cardiol. 2019 Sep 1;290:138-143. doi: 10.1016/j.ijcard.2019.05.016. Epub 2019 May 13.
9
Pressure reflection in the pulmonary circulation by echocardiography in patients with left heart disease indicates reactive pulmonary hypertension.超声心动图检测左心疾病患者肺循环中的压力反射提示反应性肺动脉高压。
Int J Cardiol. 2013 Oct 9;168(4):4222-7. doi: 10.1016/j.ijcard.2013.07.153. Epub 2013 Aug 6.
10
Novel Noninvasive Assessment of Pulmonary Arterial Stiffness Using Velocity Transfer Function.应用速度传递函数评估肺动脉僵硬度的新方法。
J Am Heart Assoc. 2018 Sep 18;7(18):e009459. doi: 10.1161/JAHA.118.009459.

引用本文的文献

1
John Newman, M.D. remembered.缅怀约翰·纽曼医生。
Pulm Circ. 2024 May 27;14(2):e12389. doi: 10.1002/pul2.12389. eCollection 2024 Apr.
2
Vitamin C deficiency can lead to pulmonary hypertension: a systematic review of case reports.维生素 C 缺乏可导致肺动脉高压:病例报告的系统评价。
BMC Pulm Med. 2024 Mar 19;24(1):140. doi: 10.1186/s12890-024-02941-x.
3
Pulmonary Vascular Resistance to Predict Right Heart Failure in Patients Undergoing Left Ventricular Assist Device Implantation.肺血管阻力对预测接受左心室辅助装置植入患者的右心衰竭情况
J Clin Med. 2024 Jan 14;13(2):462. doi: 10.3390/jcm13020462.
4
Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group.推进肺动脉高压知识的真实世界证据:现状、挑战与机遇。肺血管研究所创新药物开发倡议真实世界证据工作组的共识声明。
Pulm Circ. 2023 Dec 21;13(4):e12317. doi: 10.1002/pul2.12317. eCollection 2023 Oct.
5
Molecular Pathways in Pulmonary Arterial Hypertension.肺高血压的分子途径。
Int J Mol Sci. 2022 Sep 2;23(17):10001. doi: 10.3390/ijms231710001.
6
Normalization of Four Different Types of Pulmonary Hypertension After Atrial Septal Defect Closure.房间隔缺损封堵术后四种不同类型肺动脉高压的正常化
Front Cardiovasc Med. 2022 Jun 10;9:876755. doi: 10.3389/fcvm.2022.876755. eCollection 2022.
7
Comparing Diagnosis and Treatment of Pulmonary Hypertension Patients at a Pulmonary Hypertension Center versus Community Centers.肺动脉高压中心与社区中心对肺动脉高压患者的诊断与治疗比较。
Diseases. 2022 Jan 7;10(1):5. doi: 10.3390/diseases10010005.
8
Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances.肺动脉高压:诊断、治疗与新进展。
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1472-1487. doi: 10.1164/rccm.202012-4317SO.